This paper is in the following e-collection/theme issue:

Surveillance Systems (514) Public (e)Health, Digital Epidemiology and Public Health Informatics (1008) Descriptive Epidemiology and Population Size Estimates (140)

Published on in Vol 8, No 12 (2022): December

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/34809, first published .
The Global, Regional, and National Burden and Trends of NAFLD in 204 Countries and Territories: An Analysis From Global Burden of Disease 2019

The Global, Regional, and National Burden and Trends of NAFLD in 204 Countries and Territories: An Analysis From Global Burden of Disease 2019

The Global, Regional, and National Burden and Trends of NAFLD in 204 Countries and Territories: An Analysis From Global Burden of Disease 2019

Authors of this article:

Huilong Chen1 Author Orcid Image ;   Yuan Zhan2 Author Orcid Image ;   Jinxiang Zhang3 Author Orcid Image ;   Sheng Cheng4 Author Orcid Image ;   Yuhao Zhou2 Author Orcid Image ;   Liyuan Chen5 Author Orcid Image ;   Zhilin Zeng1 Author Orcid Image
Article Authors Cited by (40) Tweetations (3) Metrics

Journals

  1. Barbalho S, Laurindo L, Tofano R, Flato U, Mendes C, de Alvares Goulart R, Briguezi A, Bechara M. Dysmetabolic Iron Overload Syndrome: Going beyond the Traditional Risk Factors Associated with Metabolic Syndrome. Endocrines 2023;4(1):18 View
  2. Liu H, Qi J, Yang J, Liu F, Li X, Yin P, Wang L, Liang Z, Wei L, Rao H, Zhou M. Burden of liver complications related to non‐alcoholic fatty liver disease in China from 2005 to 2019: Observations from the Global Burden of Disease Study, 2019. Diabetes, Obesity and Metabolism 2023;25(S1):43 View
  3. Zhang N, Wu J, Wang Q, Liang Y, Li X, Chen G, Ma L, Liu X, Zhou F. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer Journal 2023;13(1) View
  4. Paik J, Henry L, Younossi Y, Ong J, Alqahtani S, Younossi Z. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatology Communications 2023;7(10) View
  5. Li J, Wang Q, Ni W, Liu C, Li Z, Qi X. Global health burden of cirrhosis and other chronic liver diseases (CLDs) due to non-alcoholic fatty liver disease (NAFLD): A systematic analysis for the global burden of disease study 2019. Global Transitions 2023;5:160 View
  6. Tang H, Zhang N, Liu X, Xiao H, Zhang H, Zhou K, Deng J. Incidence Trends of Inherited Anemias at the Global, Regional, and National Levels Over Three Decades. Journal of Epidemiology and Global Health 2023;14(1):72 View
  7. Yu G, Chen Q, Chen J, Liao X, Xie H, Zhao Y, Liu J, Sun J, Chen S. Gut microbiota alterations are associated with functional outcomes in patients of acute ischemic stroke with non-alcoholic fatty liver disease. Frontiers in Neuroscience 2023;17 View
  8. Liang Y, Zhang N, Wang M, Liu Y, Ma L, Wang Q, Yang Q, Liu X, Zhou F, Wei Y. Distributions and Trends of the Global Burden of Colorectal Cancer Attributable to Dietary Risk Factors over the Past 30 Years. Nutrients 2023;16(1):132 View
  9. Yi W, Wu H, Fu W, Feng H, Huang J, Li H, Song Z, Chen Y, Zheng Y, She S. Prevalence and Risk Factors of Non-Alcoholic Fatty Liver Disease (NAFLD) in Non-Obese Patients with Schizophrenia: A Retrospective Study. Diabetes, Metabolic Syndrome and Obesity 2024;Volume 17:841 View
  10. Allen A, Charlton M, Cusi K, Harrison S, Kowdley K, Noureddin M, Shubrook J. Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting. Postgraduate Medicine 2024;136(3):229 View
  11. Zhang J, Zhou J, He Z, Li H. Bacteroides and NAFLD: pathophysiology and therapy. Frontiers in Microbiology 2024;15 View
  12. Enomoto H, Akuta N, Hikita H, Suda G, Inoue J, Tamaki N, Ito K, Akahane T, Kawaoka T, Morishita A, Ogawa E, Tateishi R, Yoshiji H. Etiological changes of liver cirrhosis and hepatocellular carcinoma‐complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021. Hepatology Research 2024;54(8):763 View
  13. Zhang Q, Zhao W, Sun Z, Dong X, Zhu L, Zhang Z, Chen X, Hu Y, Du M, Li J, Zhang Y. Peroxisome proliferator-activated receptors gama ameliorates liver fibrosis in non-alcoholic fatty liver disease by inhibiting TGF-β/Smad signaling activation. Frigid Zone Medicine 2024;4(1):12 View
  14. Al Mahtab M, Shrestha A, Singh S, Anirvan P, Sudhamshu K. Nonalcoholic Fatty Liver Disease vs Metabolic-associated Fatty Liver Disease vs Metabolic Dysfunction-associated Steatotic Liver Disease: What\'s in the Name?. Euroasian journal of hepato-gastroenterology 2024;14(1):1 View
  15. Chan W, Wong V, Adams L, Nguyen M. MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD. Hepatology International 2024;18(S2):909 View
  16. Shakhshir M, Zyoud S. Mapping global research trends: Nutrition associations with nonalcoholic fatty liver disease - a Scopus bibliometric analysis. World Journal of Gastroenterology 2024;30(24):3106 View
  17. Malladi N, Lahamge D, Somwanshi B, Tiwari V, Deshmukh K, Balani J, Chakraborty S, Alam M, Banerjee S. Paricalcitol attenuates oxidative stress and inflammatory response in the liver of NAFLD rats by regulating FOXO3a and NFκB acetylation. Cellular Signalling 2024;121:111299 View
  18. Zhong H, Zhang K, Lin L, Yan Y, Shen L, Chen H, Liang X, Chen J, Miao Z, Zheng J, Chen Y. Two-week continuous glucose monitoring-derived metrics and degree of hepatic steatosis: a cross-sectional study among Chinese middle-aged and elderly participants. Cardiovascular Diabetology 2024;23(1) View
  19. Guo W, Li Z, Anagnostopoulos G, Kong W, Zhang S, Chakarov S, Shin A, Qian J, Zhu Y, Bai W, Cexus O, Nie B, Wang J, Hu X, Blériot C, Liu Z, Shen B, Venteclef N, Su B, Ginhoux F. Notch signaling regulates macrophage-mediated inflammation in metabolic dysfunction-associated steatotic liver disease. Immunity 2024;57(10):2310 View
  20. Yang Z, Li A, Jiang Y, Maidaiti X, Wu Y, Jin Y. Global burden of metabolic dysfunction-associated steatotic liver disease attributable to high fasting plasma glucose in 204 countries and territories from 1990 to 2021. Scientific Reports 2024;14(1) View
  21. Lu F, Liu J, She B, Yang H, Ji F, Zhang L. Global Trends and Inequalities of Liver Complications Related to Metabolic Dysfunction‐Associated Steatotic Liver Disease: An Analysis From 1990 to 2021. Liver International 2025;45(4) View
  22. Zhang H, Yang X, Chen J, Jiang Q, Yao S, Chen L, Xiang X. Investigation of the mechanism by which Tegillarca granosa polysaccharide regulates non-alcoholic fatty liver disease in mice by modulating Lactobacillus Johnsonii. International Journal of Biological Macromolecules 2024;282:137259 View
  23. Tan L, Xu S. Association between serum antibodies to oral microorganisms and nonalcoholic fatty liver disease in adults. BMC Oral Health 2024;24(1) View
  24. Kim Y, Kim J, Seo E, Kim K, Lee J, Kim J, Kang H. Association Between Fatty Liver Index and Incidence of Cataract Surgery in Individuals Aged 50 Years and Older Based on the Korean National Health Insurance Service-Health Screening Cohort (NHIS-HEALS) Data: Longitudinal Retrospective Cohort Study. JMIR Public Health and Surveillance 2024;10:e57168 View
  25. Hong Y, Chen X, Yuan H, Huang Z, Tao S, Xie F, Xie W. Novel non-HDLc/HDLc ratio for predicting MASLD: a cross-sectional study in a Chinese health screening population. BMC Gastroenterology 2024;24(1) View
  26. Wang J, Du J, Wang M, Jin M, Tang Z, Mao Y. Global, regional, and national burden of NAFLD in youths and young adults aged 15–39 years, 1990–2021, its attributable risk factors, and projections to 2035: a systematic analysis of the Global Burden of Disease Study 2021. Frontiers in Nutrition 2025;12 View
  27. Åström H, Takami Lageborn C, Hagström H. Psychosocial risks in metabolic dysfunction-associated steatotic liver disease. Expert Review of Gastroenterology & Hepatology 2025;19(3):273 View
  28. Ruan S, Huang L, Song J, Yi Z, Sun W, Zhou F, Feng C, Du G, Xie J, Lu Y, Fan G. Global burden trends and forecasts for MAFLD in adolescents and young adults from 1990 to 2021. Scientific Reports 2025;15(1) View
  29. Davidson J, Brewer H, Rice C, Carvalho S, Kim Y. Estimating the clinical and healthcare burden of metabolic dysfunction-associated steatohepatitis in England: a retrospective cohort study using routinely collected healthcare data from 2011 to 2020. BMJ Open 2025;15(4):e095761 View
  30. Sarkoohi Z, Bastan M, Khajuei Gharaei M, Iranmanesh M, Adinepour A, Khajezade R, Bahri F, Akhlaghi F, Kadkhodamanesh A, Pourghadamyari H, Sharifi H, Eslami O, Nejadghaderi S. Epidemiological trends and burden of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa region: a 32-year analysis of health impact. Journal of Health, Population and Nutrition 2025;44(1) View
  31. Cho S, Hwang S, Kim H, Kim S, Kang Y, Yun J, Park J. Association between long-term exposure to ambient air pollution and an increased risk of steatotic liver disease. Scientific Reports 2025;15(1) View
  32. Datta D, Seshadri K, Ghosal S. MISHTI study evaluating hepatic fibrosis in type 2 diabetes patients in India. Scientific Reports 2025;15(1) View
  33. Wei J, Lin S, Zhang S, Fan L, Jiang L, Xia F, Li Z, Chen L, Zou Z, Wang T. Global, regional, and national time trends in prevalence of metabolic dysfunction associated steatotic liver disease among women of reproductive age: an age-period-cohort analysis for the global Burden of Disease 2021 study. Annals of Medicine 2025;57(1) View
  34. Abaalkhail F, Sanai F, AlSwat K, Alzanbagi A, Aljedai A, Alshehri A, Alfadda A, Alghamdi H, Almadi M, Aleissa M, Ismail M, Alsifri S, Alzahrani T, Alqahtani S, Al Hamoudi W. Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards. Saudi Journal of Gastroenterology 2025 View
  35. Pereira L, Bregion P, Ivano V, de Barros F, de França G, Scremin G, de Oliveira Alves J, de Araújo L, Fonseca P, Braga J, Cazzo E. Efficacy of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Hepatic Steatosis and Fibrosis Markers: A Meta-analysis of Randomized Clinical Trials. Obesity Surgery 2025;35(10):4520 View
  36. Hasanatuludhhiyah N, Mustika A, Kalanjati V, Miftahussurur M, Wakuda H, Uemura N. Clinacanthus nutans leaf extract prevents metabolic dysfunction-associated steatotic liver (MASL) to metabolic dysfunction-associated steatohepatitis (MASH) progression in western diet-fed C57BL/6 mice. Pharmacia 2025;72:1 View
  37. Li Z, Jiang S, Chen R, Zhang Z, Zheng L, He H, Feng R, Du S, Qiu W, Ye W. Associations between metabolic dysfunction-associated fatty liver disease and carotid and femoral atherosclerosis: a population-based cross-sectional study. Lipids in Health and Disease 2025;24(1) View
  38. Zhang K, Li S, Sun X, Ma H, Li Y, Pan Y, Liu J, Geng X, Wan Y, Wu D. Truncated thrombospondin-1 polypeptide alleviates non-alcoholic fatty liver disease induced by palmitic acid and high-fat diets. International Journal of Biological Macromolecules 2025;331:148308 View
  39. Naik C. Assessment and Improvement of Patient Knowledge on Liver Cirrhosis Prevention Using Structured Teaching in a Hospital Setting. Nigerian Postgraduate Medical Journal 2025;32(4):405 View
  40. Al-Busafi S, Eslam M. Liver Transplantation in the Era of Metabolic Dysfunction–Associated Fatty Liver Disease: Challenges, Ethical Dilemmas, and Future Directions. Transplantology 2025;6(4):35 View